ChiCTR-OIC-17010625
结束
/
/
/
2017-02-02
/
/
退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
研究富血小板血漿注射治療退化性膝關節炎
单臂
Ⅱ期
NA
/
NA
/
12
/
1990-01-01
1990-01-01
/
1) Aged 45 to 75 years old; 2) Self-reported symptoms consistent with KOA per American College of Rheumatology guidelines; 3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question "What is the average level of your left/right knee pain?" 4) Failed 6 months of usual care; 5) Clinical evidence of KOA according to the American College of Rheumatology guidelines; 6) Radiographic evidence of KOA with Kellgren Lawerance (KL).；
登录查看1) Pregnancy; 2) On anticoagulation, immunosuppressive or daily opioid therapy; 3) History of collagen tissue or other autoimmune disorders; 4) Hematological diseases; 5) Severe cardiovascular diseases; 6) Prior or planned total knee replacement of the affected knee; 7) Allergy or intolerance to acetaminophen or xylocaine; 8) Body mass index (BMI) ≥ 35 kg/m2; 9) Co-morbidity severe enough to prevent reliable or safe study participation; 10) Subjects who cannot read or write in the Chinese Consent form; 11) Interim knee joint infectious arthritis or trauma; 12) Hemoglobin level < 11g/dL; 13) Platelet concentration < 150,000/mm3; 14) Clinical examination suggesting that the patient is not appropriate due to comorbid knee or other conditions.；
登录查看The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
/
精准药物2024-11-22
亚泰制药2024-11-22
医药时间2024-11-21
一度医药2024-11-21
新药创始人2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
药时空2024-11-21
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
